fig
cytokin
level
balf
day
inocul
prrsv
mock
challeng
medium
noninfect
cell
cultur
data
express
mean
sem
pig
group
pig
group
brockmeier
et
al
cviasmorg
clinic
vaccin
immunolog
porcin
reproduct
respiratori
syndrom
prr
one
devast
costli
diseas
swine
industri
worldwid
overal
adapt
immun
respons
prr
viru
prrsv
weak
result
delay
elimin
viru
host
inferior
vaccin
protect
prrsv
shown
induc
meager
alpha
interferon
respons
hypothes
elev
level
earli
infect
would
shorten
induct
time
increas
element
adapt
immun
respons
test
measur
antibodi
cellmedi
immun
pig
administr
nonrepl
human
adenoviru
type
vector
express
porcin
time
prrsv
infect
compar
result
pig
infect
prrsv
alon
viremia
delay
decreas
viral
load
sera
pig
administ
although
seroconvers
slightli
delay
pig
receiv
probabl
due
earli
reduct
viral
replic
littl
differ
overal
neutral
antibodi
respons
seen
howev
increas
number
virusspecif
cell
detect
pig
receiv
well
alter
cytokin
profil
lung
day
postinfect
indic
presenc
time
infect
alter
innat
adapt
immun
respons
prrsv
wide
dissemin
viru
swine
caus
interstiti
pneumonia
abort
lateterm
fetal
death
sow
prrsv
member
arterivirida
famili
positivesens
singlestrand
rna
primarili
infect
cell
monocyt
macrophag
lineag
infect
prrsv
character
prolong
viral
persist
current
vaccin
fail
provid
diseas
control
especi
genet
unrel
strain
recent
emerg
highli
pathogen
strain
prrsv
asia
highlight
import
find
method
control
prrsv
diseas
spread
gener
innat
adapt
immun
respons
prrsv
suppress
compar
virus
infect
respiratori
epitheli
cell
swine
influenza
viru
porcin
respiratori
coronaviru
prrsv
appear
induc
modest
level
alpha
interferon
proinflammatori
cytokin
addit
host
respons
follow
prrsv
infect
character
ineffect
delay
although
nonneutr
antibodi
rapidli
produc
follow
infect
defici
neutral
antibodi
product
cellmedi
immun
respons
typic
measur
increas
prrsvspecif
cell
take
week
develop
sever
group
report
increas
product
respons
prrsv
infect
suggest
may
immunosuppress
sinc
shown
suppress
antigenpres
cell
activ
process
present
antigen
tumor
necrosi
factor
alpha
type
ifn
express
type
interferon
import
role
innat
adapt
immun
respons
contribut
innat
antivir
immun
promot
product
antivir
mediat
pkr
doublestrand
rnadepend
protein
kinas
mx
myxoviru
resist
ifninduc
gtpase
elicit
nk
cell
activ
kill
virusinfect
cell
also
play
role
adapt
immun
respons
induc
matur
dendrit
cell
profession
antigenpres
cell
macrophag
develop
matur
along
promot
b
cell
differenti
plasma
cell
sever
mechan
prrsv
inhibit
type
ifn
product
propos
multipl
mechan
may
appli
prrsv
shown
inhibit
doublestrand
rna
activ
interferon
regulatori
factor
via
inactiv
promot
stimul
adaptor
molecul
retino
acidinduc
gene
pathway
other
propos
prrsv
interfer
modif
ib
either
ovarian
tumor
domainmedi
inhibit
polyubiquitin
inhibit
phosphoryl
ultim
lead
impair
nfb
activ
previou
report
show
use
nonrepl
adenoviru
type
vector
deliv
porcin
pig
increas
level
time
challeng
delay
prrsv
viremia
lessen
sever
diseas
goal
studi
test
effect
elev
earli
infect
time
qualiti
adapt
immun
respons
prrsv
littl
produc
prrsv
infect
play
role
develop
adapt
immun
respons
well
innat
immun
respons
hypothes
might
one
reason
inadequ
adapt
respons
viru
test
hypothesi
follow
aspect
adapt
immun
respons
antibodyand
cellmedi
immun
pig
simultan
administ
prrsv
compar
respons
pig
expos
prrsv
recombin
replicationdefect
human
adenoviru
type
use
deliv
porcin
previous
describ
twentyeight
pig
divid
group
pig
given
follow
treatment
group
prrsv
group
prrsv
group
express
prrsv
day
experi
pig
given
focusform
unit
ffu
respect
construct
intramuscularli
neck
pig
group
challeng
median
cell
cultur
infecti
dose
ccid
strain
prrsv
intranas
pig
group
mock
challeng
medium
noninfect
cell
cultur
blood
sampl
collect
day
weekli
day
four
five
pig
group
euthan
day
challeng
prrsv
five
pig
group
euthan
day
challeng
prrsv
elisa
level
sera
determin
enzymelink
immunosorb
assay
elisa
use
monoclon
antibodi
mab
mab
conjug
horseradish
peroxidas
pbl
interferon
sourc
previous
describ
briefli
plate
coat
g
mab
sampl
set
duplic
ad
well
plate
incub
wash
prior
addit
peroxidaseconjug
plate
wash
tetramethylbenzidin
substrat
solut
ad
well
optic
densiti
measur
nm
elisa
plate
reader
quantifi
recombin
porcin
use
standard
concentr
calcul
basi
standard
curv
prrsv
isol
detect
viremia
measur
viru
isol
realtim
revers
transcriptionpcr
rtpcr
viru
isol
perform
ad
l
serum
well
plate
contain
monolay
cell
ml
cell
cultur
medium
h
medium
well
remov
replac
fresh
medium
well
examin
cytopath
effect
cpe
assess
posit
neg
week
cultur
realtim
rtpcr
assay
prrsv
use
quantifi
viral
rna
vrna
serum
pig
previous
describ
briefli
viral
rna
isol
l
serum
sampl
use
commerci
kit
viral
rna
isol
kit
qiagen
viral
rna
elut
l
eight
microlit
elut
rna
sampl
use
onestep
rtpcr
kit
qiagen
accord
manufactur
recommend
viral
rna
extract
stock
viru
standard
curv
dilut
gener
use
onestep
rtpcr
rna
extract
sampl
result
express
amount
vrna
rel
standard
curv
prrsv
antibodi
detect
seroconvers
prrsv
determin
elisa
kit
elisa
sampletoposit
sp
ratio
gener
collect
serum
sampl
perform
herdcheck
prr
elisa
idexx
laboratori
accord
manufactur
instruct
virusneutr
antibodi
respons
determin
use
fluoresc
focu
neutral
ffn
assay
previous
describ
briefli
dilut
heatinactiv
serum
sampl
incub
homolog
viru
isol
prior
infect
cell
endpoint
report
highest
serum
dilut
show
greater
reduct
number
fluoresc
foci
elispot
assay
assess
antigenspecif
respons
approxim
ml
blood
collect
time
point
indic
bd
vacutain
cpt
tube
sodium
citrat
peripher
blood
mononuclear
cell
pbmc
fraction
collect
accord
manufactur
recommend
pbmc
wash
rpmi
invitrogen
pass
screen
filter
wash
second
time
enumer
enzymelink
immunosorb
spot
elispot
assay
cell
perform
previous
describ
slight
modif
briefli
membran
plate
prewet
ethanol
wash
coat
overnight
gml
bd
bioscienc
next
day
plate
wash
block
complet
rpmi
rpmi
fetal
bovin
serum
mm
lglutamin
antibioticantimycot
invitrogen
gentamicin
h
block
medium
remov
pbmc
plate
per
well
appropri
well
treat
live
homolog
prrsv
multipl
infect
control
marc
medium
phytohemagglutinin
pha
ad
final
concentr
gml
treatment
triplic
plate
incub
h
co
h
plate
wash
incub
detect
antibodi
gml
bd
bioscienc
h
plate
wash
develop
use
elispot
blue
color
modul
r
system
accord
manufactur
recommend
plate
scan
spot
enumer
use
ctlimmunospot
uv
analyz
immunospot
softwar
number
pbmc
sampl
analyz
treatment
group
rang
multiplex
cytokin
assay
approxim
ml
bronchoalveolar
lavag
fluid
balf
centrifug
g
min
pellet
cellular
debri
cellfre
balf
test
level
searchlight
multiplex
elisa
perform
accord
manufactur
recommend
aushon
biosystem
billerica
averag
duplic
well
sampl
use
statist
analysi
statist
analysi
viremia
elispot
assay
antibodi
respons
data
analyz
use
mix
linear
model
repeat
measur
sa
version
window
sa
institut
inc
linear
combin
leastsquar
sampl
estim
use
priori
contrast
test
either
signific
p
treatment
effect
interact
effect
time
point
experiment
treatment
comparison
treatment
group
made
time
point
use
level
signific
p
assess
statist
differ
cytokin
data
compar
use
oneway
analysi
varianc
tukey
posttest
signific
level
p
elisa
run
serum
sampl
determin
magnitud
durat
product
respons
administr
andor
prrsv
infect
detect
serum
pig
day
pig
group
given
similar
level
serum
high
day
declin
rapidli
fig
level
pig
given
challeng
prrsv
peak
day
much
lower
peak
level
induc
fig
viremia
viral
rna
load
viru
isol
quantit
pcr
use
determin
extent
viremia
measur
degre
viru
replic
pig
prrsv
isol
serum
mockinfect
pig
sampl
prrsvinfect
pig
taken
day
prrsv
detect
viru
isol
serum
pig
receiv
earlier
serum
pig
receiv
indic
presenc
delay
viremia
fig
viru
isol
sera
pig
group
earli
day
postinfect
wherea
earliest
isol
viru
sera
pig
group
receiv
day
differ
viru
isol
two
experiment
group
pronounc
day
postinfect
isol
prrsv
serum
sampl
group
addit
level
prrsv
serum
detect
quantit
pcr
day
also
significantli
lower
pig
receiv
fig
even
though
incid
detect
prrsv
serum
time
similar
group
later
time
point
postinfect
signific
differ
amount
vrna
detect
challeng
group
day
postinfect
prrsv
isol
lung
lavag
fluid
prrsvchalleng
pig
regardless
treatment
data
shown
antibodi
respons
elisa
run
serum
sampl
determin
pig
seroconvert
total
antibodi
respons
prrsv
basi
elisa
result
pig
given
challeng
prrsv
seroconvert
prrsv
later
pig
challeng
prrsv
given
fig
use
recommend
cutoff
valu
sp
ratio
pig
group
given
averag
seroconvert
prrsv
day
postinfect
sp
ratio
day
significantli
higher
pig
pig
group
given
none
seroconvert
day
day
signific
differ
antibodi
level
group
challeng
prrsv
none
pig
noninfect
group
seroconvert
prrsv
idexx
elisa
use
measur
seroconvers
specif
measur
neutral
antibodi
level
better
evalu
neutral
antibodi
respons
ffn
assay
perform
trend
toward
increas
neutral
antibodi
level
rapid
appear
neutral
antibodi
day
group
given
differ
statist
signific
fig
antigenspecif
respons
better
understand
effect
administr
cellular
immun
respons
prrsv
elispot
assay
use
enumer
number
antigenspecif
cell
isc
circul
peripher
blood
day
follow
challeng
prrsvspecif
isc
detect
regardless
administr
howev
day
significantli
isc
pig
receiv
overal
higher
number
isc
detect
peripher
blood
cell
pig
given
day
number
significantli
higher
day
fig
subset
pig
group
euthan
day
postinfect
evalu
local
host
respons
lung
gener
trend
toward
increas
level
detect
balf
prrsvinfect
pig
regardless
administr
noninfect
pig
fig
howev
prrsvinfect
pig
given
lower
level
prrsvinfect
pig
given
though
differ
statist
signific
remain
cytokin
analyz
express
similar
level
group
prrsvinfect
pig
fig
signific
differ
level
among
group
data
shown
pleiotrop
cytokin
involv
mani
aspect
host
immun
respons
innat
adapt
level
exert
potent
antivir
effect
initi
product
variou
antivir
mediat
hinder
viral
replic
packag
also
act
antigenpres
cell
enhanc
abil
activ
lymphocyt
product
cytokin
express
antigenpresent
molecul
addit
act
directli
cell
drive
matur
cell
effector
cell
typic
produc
respons
viral
infect
well
accept
prrsv
induc
strong
respons
may
secondarili
affect
develop
adapt
immun
respons
hypothes
administr
recombin
protein
vivo
express
clone
gene
may
enhanc
host
respons
prrsv
aid
clearanc
increas
adapt
immun
previou
report
group
show
prophylact
ad
ministr
pig
result
increas
level
circul
approxim
day
abl
attenu
prrsv
diseas
sever
given
day
prior
prrsv
exposur
howev
effect
develop
antigenspecif
immun
respons
consid
first
studi
studi
report
extend
day
postinfect
order
monitor
prrsvspecif
respons
time
administr
also
alter
assess
effect
construct
potenti
adjuv
metaphylact
given
coincid
potenti
exposur
prrsv
exampl
pig
move
new
facil
andor
mix
pig
potenti
infect
prrsv
similar
result
report
prior
studi
current
studi
initi
delay
detect
vrna
sera
pig
given
construct
concurr
time
serum
level
highest
wherea
day
postinfect
pig
previou
experi
virem
whether
receiv
major
pig
receiv
experi
becom
virem
day
like
due
time
administr
specif
given
day
prior
infect
previou
experi
oppos
day
prrsv
challeng
experi
unlik
previou
experi
howev
exposur
result
signific
decreas
amount
prr
vrna
day
postinfect
although
affect
incid
viremia
time
period
thu
administr
construct
prevent
occurr
viremia
significantli
decreas
amount
vrna
circul
blood
data
demonstr
singl
dose
administ
day
prrsv
challeng
control
earli
viral
replic
viremia
lower
peak
viru
level
found
serum
prior
report
demonstr
onset
viremia
pig
given
low
dose
prrsv
delay
compar
onset
viremia
pig
receiv
higher
dose
although
amount
vrna
subsequ
detect
sera
unaffect
mirror
delay
viremia
observ
previou
experi
give
day
prior
challeng
prrsv
current
experi
delay
onset
viremia
also
subsequ
decreas
viral
load
peripher
blood
well
thu
unlik
alon
control
viral
load
current
experi
would
expect
vrna
level
group
level
return
normal
group
day
vrna
level
remain
rel
low
group
specul
addit
control
activ
mechan
initi
administr
work
warrant
understand
innat
antivir
respons
defin
mechan
control
viral
load
earli
time
point
follow
administr
evalu
adapt
immun
respons
data
show
administr
day
prrsv
challeng
significantli
alter
ensu
cell
respons
less
pronounc
effect
antibodi
respons
seroconvers
measur
idexx
elisa
delay
pig
given
construct
compar
pig
given
construct
presum
due
delay
viral
replic
andor
antigen
load
howev
detect
day
postinfect
signific
differ
group
day
postinfect
neutral
antibodi
titer
also
differ
significantli
two
group
though
trend
toward
increas
neutral
titer
day
group
appreci
howev
increas
number
antigenspecif
isc
peripheri
pig
given
construct
result
similar
report
meier
et
al
coadminist
modifi
live
prrsv
vaccin
found
increas
prrsv
antigenspecif
isc
effect
product
antiviru
antibodi
known
effect
antigenpres
cell
also
shown
act
directli
cell
drive
differenti
effector
cell
review
refer
contribut
isc
prrsv
clearanc
clearli
defin
difficult
assess
contribut
current
studi
viral
clearanc
control
sera
appar
day
postinfect
prrsv
isc
detect
peripher
blood
day
postinfect
neutral
antibodi
titer
detect
pig
group
day
although
viral
load
decreas
time
point
sever
report
suggest
neutral
antibodi
correl
decreas
viremia
paper
suggest
titer
must
extrem
high
provid
protect
sinc
attempt
rechalleng
know
whether
chang
immun
respons
prrsv
seen
presenc
would
efficaci
prevent
clinic
sign
induc
viral
clearanc
pig
reexpos
homolog
heterolog
prrsv
studi
would
need
explor
possibl
presenc
prrsv
challeng
alter
cytokin
profil
observ
lung
lavag
fluid
day
postinfect
although
level
unchang
trend
toward
lower
level
well
proinflammatori
cytokin
whether
delay
viral
replic
lower
viral
titer
andor
activ
mechan
initi
increas
level
influenc
differ
unknown
result
reflect
snapshot
time
howev
prrsv
induct
postul
least
partial
respons
immunosuppress
effect
thu
tempt
specul
decreas
may
associ
increas
prrsvspecif
isc
detect
pig
administ
overal
demonstr
administr
time
challeng
reduc
sever
prrsv
diseas
decreas
vrna
load
howev
depend
correl
protect
prrsv
identifi
continu
difficult
assess
impact
differ
therapeut
andor
adjuv
specif
immun
paramet
time
without
rechalleng
unabl
say
sure
whether
increas
antigenspecif
cell
would
actual
contribut
protect
necessari
continu
identifi
factor
control
viremia
also
necessari
understand
prrsv
subvert
host
immun
respons
benefit
identifi
mechan
host
use
clear
viru
